China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
1. FDA approved Tevimbra for first-line ESCC treatment in specific patients. 2. Med. OS for Tevimbra plus chemo: 16.8 months vs. 9.6 months placebo. 3. Tevimbra's efficacy observed mainly in PD-L1 positive patients. 4. BeiGene to be renamed BeOne Medicines soon. 5. ONC stock rose 3.04% following the FDA approval announcement.